Umeå University's logo

umu.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
Alternativa namn
Publikasjoner (10 av 18) Visa alla publikasjoner
Hellman, U., Rosendal, E., Lehrstrand, J., Henriksson, J., Björsell, T., Wennemo, A., . . . Lenman, A. (2024). SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study. mBio, 15(10), Article ID e01303-24.
Åpne denne publikasjonen i ny fane eller vindu >>SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study
Vise andre…
2024 (engelsk)Inngår i: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 15, nr 10, artikkel-id e01303-24Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1–5) and severe COVID-19 (WHO-CPS, 6–9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.

sted, utgiver, år, opplag, sider
American Society for Microbiology, 2024
Emneord
COVID-19, hyaluronan, hyaluronic acid, SARS-CoV-2, lung impairment, 3D-lung model
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-229944 (URN)10.1128/mbio.01303-24 (DOI)001318493400001 ()39302125 (PubMedID)2-s2.0-85206959059 (Scopus ID)
Forskningsfinansiär
Swedish Heart Lung Foundation, 20200385Swedish Heart Lung Foundation, 20200325Swedish Heart Lung Foundation, 20210078Swedish Heart Lung Foundation, 20200366Swedish Heart Lung Foundation, 20210049The Kempe Foundations, JCK-1827Umeå University, 978018Umeå University, 964781Nyckelfonden, OLL-938628Nyckelfonden, OLL-961416Sjukvårdsregionala forskningsrådet Mellansverige, RFR-968856Sjukvårdsregionala forskningsrådet Mellansverige, RFR-940474Swedish Research Council, 2020-06235Swedish Research Council, 2016-06514Swedish Research Council, 2021-06602Åke Wiberg Foundation, M22-0106Magnus Bergvall Foundation, 2022-186
Tilgjengelig fra: 2024-09-23 Laget: 2024-09-23 Sist oppdatert: 2024-10-28bibliografisk kontrollert
Welén, K., Rosendal, E., Gisslén, M., Lenman, A., Freyhult, E., Fonseca Rodriguez, O., . . . Josefsson, A. (2022). A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. European Urology, 81(3), 285-293
Åpne denne publikasjonen i ny fane eller vindu >>A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
Vise andre…
2022 (engelsk)Inngår i: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 81, nr 3, s. 285-293Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response.

Objective: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection.

Designs, settings, and participants: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2–positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells.

Intervention: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care.

Outcome measurements: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition.

Results and limitations: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20–0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52–4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders.

Conclusions: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted.

Patient summary: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.

sted, utgiver, år, opplag, sider
Elsevier, 2022
Emneord
COVID-19, SARS-CoV-2, Antiandrogen, Randomized trial, Enzalutamide, Bicalutamide, Androgen deprivation therapy
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-190911 (URN)10.1016/j.eururo.2021.12.013 (DOI)000809752100020 ()2-s2.0-85122412349 (Scopus ID)
Forskningsfinansiär
Knut and Alice Wallenberg Foundation, 2020.0182ProstatacancerförbundetSwedish Cancer Society, 2017/478Swedish Cancer Society, 20 1055 PjFSwedish Heart Lung Foundation, 20200385Region Västerbotten, RV-836351Region Västerbotten, RV-939769
Tilgjengelig fra: 2022-01-02 Laget: 2022-01-02 Sist oppdatert: 2025-02-18bibliografisk kontrollert
Rosendal, E., Mihai, I. S., Becker, M., Das, D., Frängsmyr, L., Persson, B. D., . . . Lenman, A. (2022). Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections. mBio, 13(3), Article ID e00892-22.
Åpne denne publikasjonen i ny fane eller vindu >>Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections
Vise andre…
2022 (engelsk)Inngår i: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 13, nr 3, artikkel-id e00892-22Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The coronavirus disease 2019, COVID-19, is a complex disease with a wide range of symptoms from asymptomatic infections to severe acute respiratory syndrome with lethal outcome. Individual factors such as age, sex, and comorbidities increase the risk for severe infections, but other aspects, such as genetic variations, are also likely to affect the susceptibility to SARS-CoV-2 infection and disease severity. Here, we used a human 3D lung cell model based on primary cells derived from multiple donors to identity host factors that regulate SARS-CoV-2 infection. With a transcriptomics-based approach, we found that less susceptible donors show a higher expression level of serine protease inhibitors SERPINA1, SERPINE1, and SERPINE2, identifying variation in cellular serpin levels as restricting host factors for SARS-CoV-2 infection. We pinpoint their antiviral mechanism of action to inhibition of the cellular serine protease, TMPRSS2, thereby preventing cleavage of the viral spike protein and TMPRSS2-mediated entry into the target cells. By means of single-cell RNA sequencing, we further locate the expression of the individual serpins to basal, ciliated, club, and goblet cells. Our results add to the importance of genetic variations as determinants for SARS-CoV-2 susceptibility and suggest that genetic deficiencies of cellular serpins might represent risk factors for severe COVID-19. Our study further highlights TMPRSS2 as a promising target for antiviral intervention and opens the door for the usage of locally administered serpins as a treatment against COVID-19.

sted, utgiver, år, opplag, sider
American Society for Microbiology, 2022
Emneord
A1AT, alpha-1-antitrypsin, antithrombin III, ATIII, COVID-19, PAI1, plasminogen activator inhibitor 1, SARS-CoV-2, serpin, TMPRSS2
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-203186 (URN)10.1128/mbio.00892-22 (DOI)000797888900001 ()35532162 (PubMedID)2-s2.0-85133144334 (Scopus ID)
Forskningsfinansiär
Science for Life Laboratory, SciLifeLabSwedish National Infrastructure for Computing (SNIC), SNIC 2020/6-251Swedish Heart Lung Foundation, 2020038Knut and Alice Wallenberg Foundation, 2020.0182Knut and Alice Wallenberg Foundation, C19R:028Swedish Society for Medical Research (SSMF)The Kempe Foundations, JCK-1827Swedish Research Council, 2016-06598
Tilgjengelig fra: 2023-01-17 Laget: 2023-01-17 Sist oppdatert: 2024-11-01bibliografisk kontrollert
Persson, B. D., Nord, S., Lindquist, R., Danskog, K., Överby, A. K., Kohl, A., . . . Arnberg, N. (2021). BAF45b is required for efficient zika virus infection of HAP1 cells. Viruses, 13(10), Article ID 2007.
Åpne denne publikasjonen i ny fane eller vindu >>BAF45b is required for efficient zika virus infection of HAP1 cells
Vise andre…
2021 (engelsk)Inngår i: Viruses, E-ISSN 1999-4915, Vol. 13, nr 10, artikkel-id 2007Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The 2016 Zika virus (ZIKV) epidemic illustrates the impact of flaviviruses as emerging human pathogens. For unknown reasons, ZIKV replicates more efficiently in neural progenitor cells (NPCs) than in postmitotic neurons. Here, we identified host factors used by ZIKV using the NCI-60 library of cell lines and COMPARE analysis, and cross-analyzed this library with two other libraries of host factors with importance for ZIKV infection. We identified BAF45b, a subunit of the BAF (Brg1/Brm-associated factors) protein complexes that regulate differentiation of NPCs to post-mitotic neurons. ZIKV (and other flaviviruses) infected HAP1 cells deficient in expression of BAF45b and other BAF subunits less efficiently than wildtype (WT) HAP1 cells. We concluded that subunits of the BAF complex are important for infection of ZIKV and other flavivirus. Given their function in cell and tissue differentiation, such regulators may be important determinants of tropism and pathogenesis of arthropod-borne flaviviruses.

sted, utgiver, år, opplag, sider
MDPI, 2021
Emneord
BAF45b, DPF1, Flavivirus, Zika virus
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-188850 (URN)10.3390/v13102007 (DOI)000792951900009 ()2-s2.0-85117010328 (Scopus ID)
Forskningsfinansiär
EU, Horizon 2020, 734584Swedish Research Council, 2017-02438Swedish Research Council, 2016-00968
Tilgjengelig fra: 2021-10-25 Laget: 2021-10-25 Sist oppdatert: 2024-01-17bibliografisk kontrollert
Zapatero-Belinchón, F. J., Moeller, R., Lasswitz, L., van Ham, M., Becker, M., Brogden, G., . . . Gerold, G. (2021). Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience, 24(12), Article ID 103469.
Åpne denne publikasjonen i ny fane eller vindu >>Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Vise andre…
2021 (engelsk)Inngår i: iScience, E-ISSN 2589-0042, Vol. 24, nr 12, artikkel-id 103469Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells.

sted, utgiver, år, opplag, sider
Elsevier, 2021
Emneord
Drugs, Virology
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-190104 (URN)10.1016/j.isci.2021.103469 (DOI)000740245300008 ()2-s2.0-85120182160 (Scopus ID)
Forskningsfinansiär
Knut and Alice Wallenberg FoundationEU, Horizon 2020, 871029
Tilgjengelig fra: 2021-12-10 Laget: 2021-12-10 Sist oppdatert: 2025-02-18bibliografisk kontrollert
Rajan, A., Palm, E., Trulsson, F., Mundigl, S., Becker, M., Persson, D., . . . Lenman, A. (2021). Heparan Sulfate Is a Cellular Receptor for Enteric Human Adenoviruses. Viruses, 13(2), Article ID 298.
Åpne denne publikasjonen i ny fane eller vindu >>Heparan Sulfate Is a Cellular Receptor for Enteric Human Adenoviruses
Vise andre…
2021 (engelsk)Inngår i: Viruses, E-ISSN 1999-4915, Vol. 13, nr 2, artikkel-id 298Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Human adenovirus (HAdV)-F40 and -F41 are leading causes of diarrhea and diarrhea-associated mortality in children under the age of five, but the mechanisms by which they infect host cells are poorly understood. HAdVs initiate infection through interactions between the knob domain of the fiber capsid protein and host cell receptors. Unlike most other HAdVs, HAdV-F40 and -F41 possess two different fiber proteins-a long fiber and a short fiber. Whereas the long fiber binds to the Coxsackievirus and adenovirus receptor (CAR), no binding partners have been identified for the short fiber. In this study, we identified heparan sulfate (HS) as an interaction partner for the short fiber of enteric HAdVs. We demonstrate that exposure to acidic pH, which mimics the environment of the stomach, inactivates the interaction of enteric adenovirus with CAR. However, the short fiber:HS interaction is resistant to and even enhanced by acidic pH, which allows attachment to host cells. Our results suggest a switch in receptor usage of enteric HAdVs after exposure to acidic pH and add to the understanding of the function of the short fibers. These results may also be useful for antiviral drug development and the utilization of enteric HAdVs for clinical applications such as vaccine development.

sted, utgiver, år, opplag, sider
MDPI, 2021
Emneord
capsid proteins, enteric adenovirus, fiber knobs, heparan sulfate, short fibers
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-181795 (URN)10.3390/v13020298 (DOI)000623302300001 ()2-s2.0-85102606288 (Scopus ID)
Tilgjengelig fra: 2021-04-01 Laget: 2021-04-01 Sist oppdatert: 2024-01-17bibliografisk kontrollert
Arnberg, N. & Lenman, A. (2021). Special issue "adenovirus pathogenesis". Viruses, 13(6), Article ID 1112.
Åpne denne publikasjonen i ny fane eller vindu >>Special issue "adenovirus pathogenesis"
2021 (engelsk)Inngår i: Viruses, E-ISSN 1999-4915, Vol. 13, nr 6, artikkel-id 1112Artikkel i tidsskrift, Editorial material (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
MDPI, 2021
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-185675 (URN)10.3390/v13061112 (DOI)2-s2.0-85108591525 (Scopus ID)
Tilgjengelig fra: 2021-07-02 Laget: 2021-07-02 Sist oppdatert: 2024-01-17bibliografisk kontrollert
Kirui, J., Abidine, Y., Lenman, A., Islam, M. K. K., Yong-Dae, G., Lasswitz, L., . . . Gerold, G. (2021). The Phosphatidylserine Receptor TIM-1 Enhances Authentic Chikungunya Virus Cell Entry. Cells, 10(7), Article ID 1828.
Åpne denne publikasjonen i ny fane eller vindu >>The Phosphatidylserine Receptor TIM-1 Enhances Authentic Chikungunya Virus Cell Entry
Vise andre…
2021 (engelsk)Inngår i: Cells, E-ISSN 2073-4409, Vol. 10, nr 7, artikkel-id 1828Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Chikungunya virus (CHIKV) is a re-emerging, mosquito-transmitted, enveloped positive stranded RNA virus. Chikungunya fever is characterized by acute and chronic debilitating arthritis. Although multiple host factors have been shown to enhance CHIKV infection, the molecular mechanisms of cell entry and entry factors remain poorly understood. The phosphatidylserine-dependent receptors, T-cell immunoglobulin and mucin domain 1 (TIM-1) and Axl receptor tyrosine kinase (Axl), are transmembrane proteins that can serve as entry factors for enveloped viruses. Previous studies used pseudoviruses to delineate the role of TIM-1 and Axl in CHIKV entry. Conversely, here, we use the authentic CHIKV and cells ectopically expressing TIM-1 or Axl and demonstrate a role for TIM-1 in CHIKV infection. To further characterize TIM-1-dependent CHIKV infection, we generated cells expressing domain mutants of TIM-1. We show that point mutations in the phosphatidylserine binding site of TIM-1 lead to reduced cell binding, entry, and infection of CHIKV. Ectopic expression of TIM-1 renders immortalized keratinocytes permissive to CHIKV, whereas silencing of endogenously expressed TIM-1 in human hepatoma cells reduces CHIKV infection. Altogether, our findings indicate that, unlike Axl, TIM-1 readily promotes the productive entry of authentic CHIKV into target cells.

sted, utgiver, år, opplag, sider
MDPI, 2021
Emneord
Chikungunya virus, CHIKV, alphavirus, enveloped virus, phosphatidylserine, T-cell immunoglobulin and mucin domain 1, TIM-1, Axl receptor tyrosine kinase, Axl, entry
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-187299 (URN)10.3390/cells10071828 (DOI)000676394100001 ()34359995 (PubMedID)2-s2.0-85114081934 (Scopus ID)
Forskningsfinansiär
Knut and Alice Wallenberg FoundationSwedish Research Council, 2017-05607
Tilgjengelig fra: 2021-09-09 Laget: 2021-09-09 Sist oppdatert: 2024-07-02bibliografisk kontrollert
Rafie, K., Lenman, A., Fuchs, J., Rajan, A., Arnberg, N. & Carlson, L.-A. (2021). The structure of enteric human adenovirus 41: A leading cause of diarrhea in children. Science Advances, 7(2), Article ID eabe0974.
Åpne denne publikasjonen i ny fane eller vindu >>The structure of enteric human adenovirus 41: A leading cause of diarrhea in children
Vise andre…
2021 (engelsk)Inngår i: Science Advances, E-ISSN 2375-2548, Vol. 7, nr 2, artikkel-id eabe0974Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Human adenovirus (HAdV) types F40 and F41 are a prominent cause of diarrhea and diarrhea-associated mortality in young children worldwide. These enteric HAdVs differ notably in tissue tropism and pathogenicity from respiratory and ocular adenoviruses, but the structural basis for this divergence has been unknown. Here, we present the first structure of an enteric HAdV-HAdV-F41-determined by cryo-electron microscopy to a resolution of 3.8 angstrom. The structure reveals extensive alterations to the virion exterior as compared to nonenteric HAdVs, including a unique arrangement of capsid protein IX. The structure also provides new insights into conserved aspects of HAdV architecture such as a proposed location of core protein V, which links the viral DNA to the capsid, and assembly-induced conformational changes in the penton base protein. Our findings provide the structural basis for adaptation of enteric HAdVs to a fundamentally different tissue tropism.

sted, utgiver, år, opplag, sider
American Association for the Advancement of Science, 2021
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-180151 (URN)10.1126/sciadv.abe0974 (DOI)000606331400035 ()33523995 (PubMedID)2-s2.0-85099241558 (Scopus ID)
Tilgjengelig fra: 2021-03-01 Laget: 2021-03-01 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Palor, M., Stejskal, L., Mandal, P., Lenman, A., Alberione, M. P., Kirui, J., . . . Grove, J. (2020). Cholesterol sensing by CD81 is important for hepatitis C virus entry. Journal of Biological Chemistry, 295(50), 16931-16948
Åpne denne publikasjonen i ny fane eller vindu >>Cholesterol sensing by CD81 is important for hepatitis C virus entry
Vise andre…
2020 (engelsk)Inngår i: Journal of Biological Chemistry, ISSN 0021-9258, E-ISSN 1083-351X, Vol. 295, nr 50, s. 16931-16948Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

CD81 plays a role in a variety of physiological and pathological processes. Recent structural analysis of CD81 indicates that it contains an intramembrane cholesterol-binding pocket and that interaction with cholesterol may regulate a conformational switch in the extracellular domain of CD81. Therefore, CD81 possesses a potential cholesterol sensing mechanism; however, its relevance for protein function is thus far unknown. In this study we investigate CD81 cholesterol sensing in the context of its activity as a receptor for hepatitis C virus. Structure-led mutagenesis of the cholesterol-binding pocket reduced CD81-cholesterol association, but had disparate effects on HCV, both reducing and enhancing CD81 receptor activity. We reasoned that this could be explained by alterations in the consequences of cholesterol binding. To investigate this further we performed molecular dynamic simulations of CD81 with and without cholesterol; this identified an allosteric mechanism by which cholesterol binding regulates the conformation of CD81. To test this, we designed further mutations to force CD81 into either the open (cholesterol unbound) or closed (cholesterol bound) conformation. The open mutant of CD81 exhibited reduced receptor activity whereas the closed mutant was enhanced. These data are consistent with cholesterol switching CD81 between a receptor active and inactive state. CD81 interactome analysis also suggests that conformational switching may modulate the assembly of CD81-partner networks. This work furthers our understanding of the molecular mechanism of CD81 cholesterol sensing, how this relates to HCV entry and CD81's function as a molecular scaffold; these insights are relevant to CD81's varied roles in health and disease.

sted, utgiver, år, opplag, sider
Elsevier, 2020
Emneord
Hepatitis C virus (HCV), cholesterol-binding protein, molecular dynamics, tetraspanin, virus entry
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-176974 (URN)10.1074/jbc.RA120.014761 (DOI)000599868700004 ()32900848 (PubMedID)2-s2.0-85097582734 (Scopus ID)
Forskningsfinansiär
Wellcome trustKnut and Alice Wallenberg Foundation
Tilgjengelig fra: 2020-11-23 Laget: 2020-11-23 Sist oppdatert: 2023-11-28bibliografisk kontrollert
Organisasjoner
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0001-5109-9408